Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 601–700 of 1,000
First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center
Hester, A., Henze, F., Travi, C., Harbeck, N., & Wuerstlein, R. (2021) · Breast Care · doi:10.1159/000514794 · Cited by 8
Self-citationCoussy, F., Deluche, É., Pistilli, B., Ladoire, S., Ferrero, J.-M., & Cottu, P. H. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.04.007 · Cited by 13
Yadav, S., Giridhar, K. V., Leone, J. P., Leon-Ferre, R. A., & Ruddy, K. J. (2021) · Breast Cancer Management · doi:10.2217/bmt-2021-0001 · Cited by 7
Staropoli, N., Geuna, E., Rinaldi, G., Bisagni, G., Scotti, V., Faggioni, G., Vannini, L., Arcara, C., Moretti, G., Gunnellini, M., et al. (2022) · Current Oncology · doi:10.3390/curroncol29090521 · Cited by 5
Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
Lüftner, D., Lux, M. P., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., et al. (2023) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2018-9184 · Cited by 6
Self-citationVassiliki, T., Gogadis, A., Christos, A., & Timotheadou, E. T. (2019) · Forum of Clinical Oncology · doi:10.2478/fco-2019-0007 · Cited by 6
Dawood, S. S., Chiu, J. W.-Y., Huang, C., Nag, S. M., Sookprasert, A., Yap, Y. S., & Yusof, M. M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1783646 · Cited by 5
Dawood, S. S., Konstantinova, M., Perazzo, F., Kim, S., Villarreal-Garza, C. M., Franco, S. X., Simon, S. D., & Elnahas, T. (2020) · Chinese Clinical Oncology · doi:10.21037/cco-20-138 · Cited by 5
“9%) in the placebo group in the premenopausal or perimenopausal patients with HR+/ HER2− mBC (60).”
BackgroundInhibiteurs de PARP dans les cancers du sein : développement clinique actuel et perspectives
Robbe, J., Moretta, J., Vicier, C., Sabatier, R., Noguès, C., & Gonçalvès, A. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.07.011 · Cited by 11
Macedo, L. S. D. N., Silva, A. S., França, A. C. W., Magliano, C. A. D. S., Meirelles, I. O., Padilla, M. P., & Santos, M. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2022.02.006 · Cited by 5
Verde, N. M. L., Damia, G. L. M., Garrone, O., Santini, D., Fabi, A., Ciccarese, M., Generali, D., Nunzi, M., Poletto, E., Ferraris, E., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01560-w · Cited by 6
“New targeted therapies which have become available are changing the natural history of MBC, and new goals have been achieved [3, 27, 28].”
BackgroundRibociclib and Endocrine Therapy in Breast Cancer. Reply.
Im, S., Lu, Y.-S., & Tripathy, D. (2019) · PubMed · doi:10.1056/nejmc1911188 · Cited by 5
Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply.
Slamon, D. J., & Jérusalem, G. (2020) · PubMed · doi:10.1056/nejmc2004229 · Cited by 4
The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2Preprint
Longhurst, A. D., Wang, K., Suresh, H. G., Ketavarapu, M., Ward, H. N., Jones, I. R., Narayan, V., Hundley, F. V., Hassan, A. Z., Boone, C. M., et al. (2024) · eLife · doi:10.7554/elife.97577 · Cited by 7
“However, this classical model of G1 regulation has recently given way to a more complex model 12 – 14 , underscored by the complexity of genetic alterations that lead to resistance to treatment with CDK4/6 inhibitors 4,12,13,15 .”
Armand, J., Kim, S., Kim, K., Son, E., Kim, M., Kalinsky, K. M., & Yang, H. W. (2025) · eLife · doi:10.7554/elife.104545 · Cited by 12
“The combination of CDK4/6i and ET has reshaped treatment for HR + /HER2– breast cancer ( Johnston et al., 2019 ; Finn et al., 2015 ; Finn et al., 2016 ; Turner et al., 2018 ; Dickler et al., 2017 ; Hortobagyi et al., 2022 ; Slamon et al., 2020 ; Im et al., 2019 ).”
Abemaciclib and Letrozole in Metastatic Male Breast Cancer
Schönfeld, L. J., Möhring, C., Strobel, R., Kaatsch, H. L., Waldeck, S. S., & Wagner, U. (2024) · Cancer Reports · doi:10.1002/cnr2.70054 · Cited by 4
Ly, E., Howard, F. M., Chen, N., Hahn, O. M., Fleming, G. F., Nanda, R., Patel, S. S., Thimothy, L., & Yang, H. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241305417 · Cited by 4
Ladoire, S., Kamga, A. M., Galland, L., Réda, M., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., Talucier, H., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00726-x · Cited by 6
Nardin, S., Arecco, L., Delucchi, V., Blondeaux, E., Stana, M., Leite, L. D. M., Weis, L. N., Hoang, G. P., Daneri, A., Bruzzone, F., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104479 · Cited by 4
Werutsky, G., Rosa, D. D., Reinert, T., Barroso‐Sousa, R., Resende, H. M., Signorini, P. A., Cronemberger, E. H., Fagundes, J. G. M., Leal, J. H. S., Guimarães, M. B., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.05.020 · Cited by 4
Fidan, M. C., Öztürk, A. E., Aydın, O., Akdağ, G., Türkoğlu, E., Çolak, R., Majidova, N., Kapağan, T., Guliyev, M., Çelik, E., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134568 · Cited by 5
TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia
Pottier, A., Park, S., Lee, Y., Liccardo, F., Yang, H., Park, J., Lorant, A., Schnekenburger, M., Brusa, D., Li, V., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218011 · Cited by 5
Finn, R. S., Rugo, H. S., Cortés, J., Loibl, S., Foley, G., Gauthier, E., Wang, Y., Kim, S., Anders, L., & Slamon, D. J. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01175-z · Cited by 7
Caputo, R., Fabi, A., Romagnoli, E., Baldini, E., Grasso, D., Fenderico, N., & Michelotti, A. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s376902 · Cited by 5
Keskinkılıç, M., Semiz, H. S., Yavuzşen, T., & Öztop, İ. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1378563 · Cited by 6
Fjermeros, K., Ghannoum, S., Geisler, S. B., Bhargava, S., Tahiri, A., Klajic, J., Lüders, T., Fongaard, M., Nawaz, M. S., Bosnjak, T., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2377531 · Cited by 7
“Ribociclib was chosen as the CDK4/6 inhibitor in the NEOLETRIB trial based on the convincing results of ribo-ciclib in the metasta tic setting, demonstra ting significan t overall survival benefit in both pre-and postmenopausal women [ 29 , 45 , 46 ].”
Lobo-Martins, S., Corredeira, P., Cavaco, A. C. M., Rodrigues, C., Piairo, P., Lopes, C., Fraga, J. S., da Silva, M. P., Alves, P., Szeneszi, L. W., et al. (2024) · Cells · doi:10.3390/cells13161391 · Cited by 5
“This fi nding is consistent with previous reports [3,36–40].”
ResultChang, S., Svensson, M., Wang, G. H., Wang, Y., Kang, H., & Park, H. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.9.942 · Cited by 6
Qureshi, Z. A., Altaf, F., Safi, A., Khanzada, M., Ghazanfar, A., & Shah, S. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002730 · Cited by 4
Benvenuti, C., Grinda, T., Rassy, E., Dixon-Douglas, J. R., Ribeiro, J. M., Zambelli, A., Santoro, A., & Pistilli, B. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01259-4 · Cited by 6
Breast Cancer: General Overview
Kavgacı, G., & Aksoy, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-75480-7_1 · Cited by 4
Xu, J., Wang, R., & Shen, K. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251324633 · Cited by 4
Huebner, H., Wurmthaler, L. A., Goossens, C., Ernst, M., Mocker, A., Krückel, A., Kallert, M., Geck, J., Limpert, M., Seitz, K., et al. (2025) · JMIR Cancer · doi:10.2196/64083 · Cited by 10
“In this study, prolonged QTc times were detected in one patient, corresponding to 6% (1/76 patients) of those receiving ribociclib therapy, which is in line with RCT findings [2-4].”
van Geel, J., Jongbloed, E. M., Moustaquim, J., van der Schoor, G., van Leeuwen‐Stok, A. E., Smid, M., van Deurzen, C. H. M., Wilting, S. M., Wesseling, J., Sonke, G. S., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00764-5 · Cited by 4
Karihtala, P. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.43645 · Cited by 5
Azim, H. A., Dawood, S. S., El-Saghir, N. S., Kassem, L. M. H., & Azim, H. A. (2019) · The Breast Journal · doi:10.1111/tbj.13637 · Cited by 5
Lipton, N. J., Jesin, J., Warner, E., Cao, X., Kiss, A., Desautels, D. N., & Jerzak, K. J. (2020) · Current Oncology · doi:10.3747/co.27.6131 · Cited by 5
Liu, S., Sun, X., Xu, X., & Lin, F. (2020) · Journal of Breast Cancer · doi:10.4048/jbc.2020.23.e55 · Cited by 5
“92) 157/484 340/484 FUL 242 52/242 152/242 MONALEESA-7 [41,44] AI+RIBO 248 Premenopausal women with HR-positive/HER2negative advanced breast cancer 0.”
BackgroundSOLAR1s: alpelisib returns to earth?
Matikas, A., & Foukakis, T. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.003 · Cited by 4
Duan, F., Song, C., Ma, Y., Jiang, K., Xu, F., Bi, X., Huang, J., Hong, R., Huang, Z., Lu, Q., et al. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s314723 · Cited by 4
Inclusion of premenopausal women in breast cancer clinical trials
Corrigan, K. L., Kouzy, R., Jaoude, J. A., Patel, R. R., Layman, R. M., Giordano, S. H., Woodward, W. A., Smith, B. D., Shaitelman, S. F., & Ludmir, E. B. (2022) · The Breast · doi:10.1016/j.breast.2022.10.013 · Cited by 4
“Some trials, such as MONALEESA 7 and MONARCH 2, have now been published showing the safety and efficacy of targeted therapy in metastatic PMBC, demonstrating the benefit of designing trials that allow for PMBC inclusion [16,17].”
BackgroundAguilar, A. D. L., Fuentes, J. D. B., Anselmi, J. O., Olalla, J., Navarro, P. F., Lorenzo, A. L. D. S., Fuentes‐Antrás, J., Rey, C. R., Candil, A. O., Moreno, F., et al. (2023) · Cancers · doi:10.3390/cancers15184452 · Cited by 4
Majumdar, S. K. D., Barik, S. K., Pattanaik, A., Das, D. K., & Parida, D. K. (2024) · Cureus · doi:10.7759/cureus.52172 · Cited by 4
BOER, R. D., Hui, R., Lim, E., Yeo, B. J., & Zdenkowski, N. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13461 · Cited by 5
Sarma, M., Abdou, Y. G., Dhakal, A., & Gandhi, S. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420976387 · Cited by 4
West, M. T., Kartika, T., Paquin, A. R., Liederbauer, E., Zheng, T. J., Lane, L., Thein, K. Z., & Shatzel, J. J. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100832 · Cited by 4
Shin, J. Y., Mathis, N. J., Wijetunga, N. A., Yerramilli, D., Higginson, D. S., Schmitt, A. M., Gomez, D. R., Yamada, Y. J., & Yang, J. T. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.100906 · Cited by 4
Stevens-Johnson syndrome in breast cancer patient treated with ribociclib
Kowalczyk, A., & Radecka, B. S. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2022.0004 · Cited by 4
Novick, D., Lee, S. Y., Koo, D. H., Szende, Á., & Colman, S. (2022) · Journal of Drug Assessment · doi:10.1080/21556660.2022.2107834 · Cited by 4
Brain, C. T., Chopra, R., Kim, S., Howard, S., & Sung, M. J. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch9 · Cited by 8
Impact of Patient Profile on CDK4/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis
Stanciu, I.-M., Orlov-Slavu, M. C., Paroșanu, A. I., & Niţipir, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073357 · Cited by 5
Decker, T. W., Brucker, C. V. M., Engel, A., Fasching, P. A., Göhler, T., Jackisch, C., Janßen, J., Köhler, A., Lüdtke-Heckenkamp, K., Lüftner, D., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105105 · Cited by 6
Fountzilas, E., Aravantinou-Fatorou, E., Dadouli, K., Economopoulou, P., Tryfonopoulos, D. J., Vernadou, A., Vorrias, E., Vagionas, A., Nikolaidi, A., Karageorgopoulou, S., et al. (2025) · Cancers · doi:10.3390/cancers17152543 · Cited by 3
“The combination of ribociclib and endocrine therapy as a first-line treatment resulted in significantly improved overall survival (OS) compared to endocrine therapy alone, both in postmenopausal and premenopausal women with HR-positive/HER2-negative advanced breast cancer [4,5].”
Nishina, T., Tanioka, M., Takada, K., Tsukioki, T., Takahashi, Y. K., Shien, T., & Toyooka, S. (2025) · Breast Cancer · doi:10.1007/s12282-025-01768-6 · Cited by 3
Lee, C., Chen, P., Jhou, H., Chang, W.-C., Chen, H., Kao, L., Hsieh, T. Y. J., & Dai, M. (2025) · The Breast · doi:10.1016/j.breast.2025.104597 · Cited by 4
“…(palbociclib, riboci-clib, or abemaciclib) to first-line endocrine therapy significantly improves progression-free survival by 10 – 15 months compared to endocrine therapy alone, with overall survival benefits ranging from 12.9 to 28.8 months depending on the agent and clinical setting [1,2].”
InfluentialFilis, P., FİLİS, N., Foukakis, T., & Matikas, A. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106062 · Cited by 3
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
Schiavoni, G., Palmese, A., Scalera, S., Cipriani, L., Mascolo, D., Vici, P., Arcuri, T., Filomeno, L., Krasniqi, E., Blandino, G., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70232 · Cited by 3
Shahraz, S., Wong, O. Y., Chotai, R., Knight, S., Globe, D., Patel, M. J., Kaushik, A., Aiyegbusi, O. L., & Calvert, M. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-000942 · Cited by 3
Aghakouchakzadeh, M., Kakavand, H., Goldberg, A. J., Accordino, M. K., Trivedi, M. S., Raikhelkar, J., & Talasaz, A. H. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70149 · Cited by 3
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies
Tan, H. N., Curigliano, G., & Yap, T. A. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.03.004 · Cited by 3
D’Angelo, A., Giudici, F., Chapman, R., Darlow, J., Kilili, H., Sobhani, N., Cinelli, M., Cappelletti, M. R., Strina, C., Milani, M., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44090292 · Cited by 3
Patnaik, A., Hamilton, E. P., Xing, Y., Rasco, D. W., Smith, L. S., Lee, Y.-L., Fang, S., Wei, J., & Hui, A. (2022) · Cancers · doi:10.3390/cancers14204996 · Cited by 3
Li, D., Jin, Y., Lin, M., Zeng, C., Guo, Q., Liu, Y., & Zhang, J. (2024) · Cancer Medicine · doi:10.1002/cam4.6762 · Cited by 5
Liu, H., Wang, H., Zhang, H., Yu, M., & Tang, Y. R. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03384-4 · Cited by 3
“In addition, studies have reported that CDK4/6 signaling promotes the continuous progression and growth of cancer cell cycles, and CDK4/6 inhibitors is used as first-line or second-line treatments for breast cancer Endocrine therapy [30, 31].”
BackgroundTreatment options in the advanced and recurrent setting for endometrial cancer: an update
Francoeur, A., Fontenot, V. E., & Tewari, K. S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2370377 · Cited by 3
Tzoumpa, S., Bejar, C., Villette, B., Louveau, B., Zelek, L. H., Martin, A., Briard, O., Bitout, D., Caux, F. A., Battistella, M., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20276 · Cited by 3
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments
Belluzzi, L., Martinelli, G., Medici, B., Farina, A., Martinelli, E., Canino, F., Caggia, F., Molinaro, A., Barbolini, M., Tamburrano, F., et al. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s489419 · Cited by 5
Doyle, C., Lohmann, A. E., Iqbal, N., Henning, J., Kulkarni, S., Califaretti, N., Hilton, J. F., Ferrario, C., Bouganim, N., Mates, M., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07580-8 · Cited by 4
Ceylan, F., Efil, S. C., Şener, D., Tenekeci, A. K., Bilgin, B., Yücel, Ş., Ceylan, E. G., Hızal, M., Şendur, M. A. N., Akıncı, M. B., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2490289 · Cited by 3
“In the PALOMA-2, PALOMA-3, MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, PFS was comparable between patients who underwent dose reduction and those who did not [20–24].”
Cervical metastasis of breast cancer: a case report and review of the literature
Shan, Y., Hou, F., Wang, Y., Han, Y., Cui, Z., & Yin, G. (2025) · Discover Oncology · doi:10.1007/s12672-025-02500-8 · Cited by 3
“…of CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) to either AI in first-line therapy or fulvestrant in second-line therapy for advanced BC has been shown to improve progression-free survival (PFS) and overall survival (OS) in both premenopausal and postmenopausal women [20, 21].”
Targeting the JAK/STAT Signaling Pathway in Breast Cancer: Leaps and Hurdles
Aho, S., Coste, C., Purcari, L., Trédan, O., Poulard, C., Méry, B., Boisvert, F., & Romancer, M. L. (2025) · Biomedicines · doi:10.3390/biomedicines13123061 · Cited by 7
CDK4/6 inhibitors: taking the place of chemotherapy?
Nasrazadani, A., & Brufsky, A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30507-8 · Cited by 3
Walbaum, B., Francisco Acevedo, C., Medina, L., Bravo, M. L., Merino, T., Mauricio Camus, A., Dominguez, F., Mondaca, S., Galindo, H., Nervi, B., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1763282 · Cited by 3
Regional Nodal Recurrence after Treatment for Breast Cancer
Albright, E. L., & Lizarraga, I. M. (2020) · Current Breast Cancer Reports · doi:10.1007/s12609-020-00392-x · Cited by 3
Артамонова, Е. В., Kovalenko, E. I., Болотина, Л. В., Stenina, M. B., Орлова, Р. В., & Mukhina, M. A. (2020) · Tumors of female reproductive system · doi:10.17650/1994-4098-2020-16-3-37-45 · Cited by 6
Decker, T. W., Seifert, R., Bichler, M., Birtel, A., Fischer, G., Nonnenbroich, C., & Dechow, T. N. (2021) · Oncology Research and Treatment · doi:10.1159/000518207 · Cited by 4
Kolyadina, I. V. (2021) · Tumors of female reproductive system · doi:10.17650/1994-4098-2021-17-2-58-67 · Cited by 3
“Среди 3 представителей класса CDK4/6i (палбоциклиб, рибоциклиб, абемациклиб) только для рибоциклиба в настоящее время доказано преимущество в ОВ в 2 независимых исследованиях (MONALEESA-3 и MONALEESA-7), причем практически во всех клинических ситуациях [5].”
InfluentialLi, J., Zhang, X., Yang, C., Lv, Y., Yang, H., Kong, X., Han, M., Wang, Z., Ma, J., Han, J., et al. (2021) · Medicine · doi:10.1097/md.0000000000027710 · Cited by 5
Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations
Chengappa, M. (2022) · ONCOLOGY · doi:10.46883/2022.25920942 · Cited by 3
Laurentiis, M. D., Caputo, R., Mazza, M., Mansutti, M., Masetti, R., Ballatore, Z., Torrisi, R., Michelotti, A., Zambelli, A., Ferro, A., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00913-x · Cited by 6
Hao, C., Bai, X., Zhang, J., Meng, W., & Tong, Z. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14715 · Cited by 3
Fitzgerald, H., & Kumar, S. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.012 · Cited by 3
Yeh, C., Zhou, M., Bapodra, N., Hershman, D. L., Espinal, E., Morán, M., Rivero, M., Fojo, T., & Bates, S. E. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07131-7 · Cited by 3
Local Control of Advanced Breast Cancer—Debate in Multidisciplinary Tumor Board
Pantelimon, I., Stancu, A. M., Coniac, S., Ionescu, A.-I., Atasiei, D.-I., Georgescu, D. E., & Gales, L. N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020510 · Cited by 8
“The intervention group had a PFS of 23.8 months vs. 13.0 months in the placebo + endocrine therapy arm (HR = 0.55; 95% CI, 0.44–0.69; p -value < 0.0001) [8,37]; the updated reported median OS was 58.7 months with Ribociclib versus 48.0 months with placebo (HR = 0.76, 95% CI, 0.608–0.956) [ 38].”
InfluentialThe Role of Cyclin-Dependent Kinases on the Metastasis of Breast Cancer
Lu, Y. (2020) · Novel Approaches in Cancer Study · doi:10.31031/nacs.2020.04.000594 · Cited by 4
Self-citationНасретдинов, А. Ф., Султанбаева, Н. И., Мусин, Ш. И., Lipatov, O. N., Измайлов, А. А., Ayupov, R. Т., Меньшиков, К. В., Пушкарев, А. В., & Султанбаев, А. В. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-20-40-46 · Cited by 3
Mallet, A., Lusque, A., Lévy, C., Pistilli, B., Brain, E. G. C., Pasquier, D., Debled, M., Théry, J. C., Gonçalvès, A., Desmoulins, I., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211070362 · Cited by 3
Real-World Data with CDK4/6 Inhibitors—A Single Center Experience from Croatia
Skočilić, I., Golčić, M., Bukovica, A. M., Kolak, M., Kolovrat, D., Ropac, S., Marušić, J., Dobrila-Dintinjana, R., Badovinac, I., Ferari, A. M., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090895 · Cited by 3
“According to the MONALEESA-7 study, the estimated OS at 42 months was 70.2% in the ribociclib group and 46.0% in the placebo group [24,25].”
MethodInfluentialEndocrine-based therapy versus chemotherapy in advanced breast cancer
Robert, M., & Turner, N. C. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30686-2 · Cited by 3
Hartkopf, A. D., Emons, J., Lux, M. P., Taran, F., Overkamp, F., Tesch, H., Titzmann, A., Pöschke, P., Lüftner, D., Wallwiener, M., et al. (2020) · Der Onkologe · doi:10.1007/s00761-020-00766-x · Cited by 3
Neven, P., Rugo, H. S., Tolaney, S. M., Iwata, H., Toi, M., Goetz, M. P., Kaufman, P. A., Lu, Y., Haddad, N., Hurt, K. C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-601421/v1 · Cited by 3
Self-citationCombination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?
Wysocki, P. J. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.100128 · Cited by 3
Karhan, O., İleri, S., Urakçı, Z., Arvas, H., Kılıç, D. K., Sezgin, Y., Erçek, B. M., & Tunç, S. (2024) · Oncology · doi:10.1159/000542693 · Cited by 2
Wang, Y., Liu, L., Graff, S. L., & Cheng, L. (2024) · Histopathology · doi:10.1111/his.15395 · Cited by 3
Martos, T., Saint-Gerons, M., Masfarre, L., Castro-Henriques, M., Martinez‐García, M., Servitja, S., & Albanell, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1430341 · Cited by 2
Bobbitt, J. R., Cuellar-Vite, L., Weber-Bonk, K. L., Yancey, M. R., Majmudar, P. R., & Keri, R. A. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108196 · Cited by 4
“Such inhibitors improve progression-free survival, and in some cases, overall survival from this disease (5 – 13).”
Li, J. (2025) · Cancers · doi:10.3390/cancers17040561 · Cited by 2
“Furthermore, in advanced breast cancer, ribociclib showed a carry-over effect, resulting in a long-term OS benefit [15–17], which may be due to ribociclib’s ability to alter tumour biology and induce immunomodulatory effects, thereby influencing the response to subsequent therapies.”
Shu, H., Xiao, K., Zhu, W., Zhang, R., Tao, T., & Sun, X. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146874 · Cited by 2
When suboptimal post-protocol care in oncology trials is rewarded
Salfi, G., & Olivier, T. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115702 · Cited by 3
Wang, J., Sun, T., Tong, Z., Hu, X., Li, W., Yan, M., Liu, Y., Ouyang, Q., Liu, X., Fang, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04364-9 · Cited by 2
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.